Early access
Sign in
Not yet taking people in FrancePhase 1

First test of BIM2b in adults with glioblastoma

Tests the drug BIM2b in adults with glioblastoma, a disease of the brain.

Key facts

Who runs it
Beta Innov
Where
Clamart, FranceSee the site
Registry title
RIVKAL clinical trial for the first-in-human administration of BIM2b in participants with Glioblastoma
Status
Not yet recruiting
Phase
Phase 1
People taking part
36 people, planned
Starts
15 Sept 2027
Expected to end
15 Sept 2029
Type of study
Interventional
Record updated
21 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with glioblastoma, a type of brain tumour. It tests BIM2b in people for the first time.

Age
18 years and older
Sex
All sexes can join

Main reasons for not taking part

  • Healthy volunteers cannot join

Where in France

  • Hopital D Instruction Des Armées PercyClamart, FranceNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
First test of BIM2b in adults with glioblastomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
21 July 2026